Antihistamine Safety Questions, Liability Risks Cautioned By Aventis
This article was originally published in The Tan Sheet
Executive Summary
A switch of Allegra to nonprescription status could create the potential for unknown consumer risks and open the door to costly lawsuits, Aventis Senior VP-Medical & Regulatory Affairs Francois Nader, MD, suggested to a joint FDA advisory panel.You may also be interested in...
FDA Commissioner Logjam Broken?: NDAC’s Wood May Be Nominee
The FDA commissioner search process appears to be focusing on Nonprescription Drugs Advisory Committee member and Vanderbilt University Vice Chancellor Alastair Wood, MD
FDA Commissioner Logjam Broken?: NDAC’s Wood May Be Nominee
The FDA commissioner search process appears to be focusing on Nonprescription Drugs Advisory Committee member and Vanderbilt University Vice Chancellor Alastair Wood, MD
FDA Commissioner Logjam Broken?: NDAC’s Wood May Be Nominee
The FDA commissioner search process appears to be focusing on Nonprescription Drugs Advisory Committee member and Vanderbilt University Vice Chancellor Alastair Wood, MD
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: